Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Sep 30;64(3):345–346. doi: 10.1136/ard.2004.027979

Large scale evidence and replication: insights from rheumatology and beyond

J Ioannidis 1
PMCID: PMC1755405  PMID: 15458962

Full Text

The Full Text of this article is available as a PDF (51.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cervera Ricard, Khamashta Munther A., Font Josep, Sebastiani Gian Domenico, Gil Antonio, Lavilla Paz, Mejía Juan Carlos, Aydintug A. Olcay, Chwalinska-Sadowska Hanna, de Ramón Enrique. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003 Sep;82(5):299–308. doi: 10.1097/01.md.0000091181.93122.55. [DOI] [PubMed] [Google Scholar]
  2. Cervera Ricard, Piette Jean-Charles, Font Josep, Khamashta Munther A., Shoenfeld Yehuda, Camps María Teresa, Jacobsen Soren, Lakos Gabriella, Tincani Angela, Kontopoulou-Griva Irene. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019–1027. doi: 10.1002/art.10187. [DOI] [PubMed] [Google Scholar]
  3. Gøtzsche P. C. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989 Mar;10(1):31–56. doi: 10.1016/0197-2456(89)90017-2. [DOI] [PubMed] [Google Scholar]
  4. Gøtzsche P. C. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. Ann Rheum Dis. 2001 Apr;60(4):349–352. doi: 10.1136/ard.60.4.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hill Catherine L., LaValley Michael P., Felson David T. Secular changes in the quality of published randomized clinical trials in rheumatology. Arthritis Rheum. 2002 Mar;46(3):779–784. doi: 10.1002/art.512. [DOI] [PubMed] [Google Scholar]
  6. Huizinga Tom W. J., Pisetsky David S., Kimberly Robert P. Associations, populations, and the truth: recommendations for genetic association studies in Arthritis & Rheumatism. Arthritis Rheum. 2004 Jul;50(7):2066–2071. doi: 10.1002/art.20360. [DOI] [PubMed] [Google Scholar]
  7. Ioannidis J. P., Ntzani E. E., Trikalinos T. A., Contopoulos-Ioannidis D. G. Replication validity of genetic association studies. Nat Genet. 2001 Nov;29(3):306–309. doi: 10.1038/ng749. [DOI] [PubMed] [Google Scholar]
  8. Ioannidis John P. A. Genetic associations: false or true? Trends Mol Med. 2003 Apr;9(4):135–138. doi: 10.1016/s1471-4914(03)00030-3. [DOI] [PubMed] [Google Scholar]
  9. Ioannidis John P. A., Vassiliou Vassilios A., Moutsopoulos Haralampos M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum. 2002 Mar;46(3):741–747. doi: 10.1002/art.10221. [DOI] [PubMed] [Google Scholar]
  10. Karassa Fotini B., Tatsioni Athina, Ioannidis John P. A. Design, quality, and bias in randomized controlled trials of systemic lupus erythematosus. J Rheumatol. 2003 May;30(5):979–984. [PubMed] [Google Scholar]
  11. Kyriakidi Maria, Ioannidis John P. A. Design and quality considerations for randomized controlled trials in systemic sclerosis. Arthritis Rheum. 2002 Feb;47(1):73–81. doi: 10.1002/art1.10218. [DOI] [PubMed] [Google Scholar]
  12. Lau J., Ioannidis J. P., Schmid C. H. Summing up evidence: one answer is not always enough. Lancet. 1998 Jan 10;351(9096):123–127. doi: 10.1016/S0140-6736(97)08468-7. [DOI] [PubMed] [Google Scholar]
  13. Lexchin Joel, Bero Lisa A., Djulbegovic Benjamin, Clark Otavio. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31;326(7400):1167–1170. doi: 10.1136/bmj.326.7400.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lohmueller Kirk E., Pearce Celeste L., Pike Malcolm, Lander Eric S., Hirschhorn Joel N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003 Jan 13;33(2):177–182. doi: 10.1038/ng1071. [DOI] [PubMed] [Google Scholar]
  15. Ntzani Evangelia E., Ioannidis John P. A. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003 Nov 1;362(9394):1439–1444. doi: 10.1016/S0140-6736(03)14686-7. [DOI] [PubMed] [Google Scholar]
  16. Olkin I. Meta-analysis: reconciling the results of independent studies. 1995 Mar 15-Apr 15Stat Med. 14(5-7):457–472. doi: 10.1002/sim.4780140507. [DOI] [PubMed] [Google Scholar]
  17. Ransohoff David F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004 Apr;4(4):309–314. doi: 10.1038/nrc1322. [DOI] [PubMed] [Google Scholar]
  18. Sacks H. S., Berrier J., Reitman D., Ancona-Berk V. A., Chalmers T. C. Meta-analyses of randomized controlled trials. N Engl J Med. 1987 Feb 19;316(8):450–455. doi: 10.1056/NEJM198702193160806. [DOI] [PubMed] [Google Scholar]
  19. Wolfe F., Lassere M., van der Heijde D., Stucki G., Suarez-Almazor M., Pincus T., Eberhardt K., Kvien T. K., Symmons D., Silman A. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol. 1999 Feb;26(2):484–489. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES